Once-weekly dulaglutide combined with basal insulin may simplify diabetes management after kidney transplantation. A real-world study published in 00 compared this regimen with multiple daily insulin injections in recipients with preexisting type 2 diabetes.

Among 142 matched patients (71 per group), HbA1c remained stable in the basal insulin plus dulaglutide group (+0.06% [+0.7 mmol/mol]) but rose by 0.60% [+6.7 mmol/mol] with MDI therapy over 24 months (p = 0.02). The dulaglutide group achieved greater weight reduction (–4.93 kg vs +1.07 kg; p < 0.0001). Although estimated glomerular filtration rate (eGFR) improved slightly, differences were not statistically significant after matching, and kidney graft outcomes were comparable between groups.

These findings suggest that adding dulaglutide to basal insulin provides sustained glycemic stability, significant weight benefit, and similar renal safety, while potentially reducing injection burden after transplantation.